A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
An Escalating Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
Sponsor: AbbVie
This PHASE1 trial investigates Multiple Sclerosis and is currently completed. AbbVie leads this study, which shows 10 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
▶ Show 5 earlier versions
-
Dec 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2017 — Dec 2017 [monthly]
Recruiting PHASE1
-
Apr 2017 — Sep 2017 [monthly]
Recruiting PHASE1
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
For direct contact, visit the study record on ClinicalTrials.gov .